Company / Accounts Receivable
Mirum Pharmaceuticals, Inc. Accounts Receivable History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$123.3M
FY2025
5-year range
$3.3M / $123.3M
FY2021-FY2025
Trend
+57.5%
vs FY2024
Sector context
#48 of 115
Health Care
What the data says
At $123M, Mirum Pharmaceuticals, Inc.'s accounts receivable ranks #48 of 115 in the Health Care sector. Accounts Receivable has increased for 5 consecutive years, from $0 in FY2020 to $123M in FY2025.
Based on SEC 10-K filings.
$123M in FY2025 with a 3-year CAGR of +72.6%.
Improved from $68M to $123M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +72.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#48 of 115 in Health CareTop 42% of 115This company $123.3M Sector average $1.1B
▼
-89.0% below sector average
Key checks
Key Insights
- Mirum Pharmaceuticals, Inc.'s accounts receivable has grown for 4 consecutive years.
- 3-year CAGR of +72.6%, indicating consistent growth.
- In FY2025, accounts receivable increased 57.5% year-over-year.
- Ranks #48 out of 115 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -26.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $123.3M | +57.5% |
| FY2024 | $78.3M | +15.2% |
| FY2023 | $68.0M | +183.3% |
| FY2022 | $24.0M | +634.4% |
| FY2021 | $3.3M | - |
| FY2020 | $0 | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026